SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma
The aim of this study is to observe the efficacy and safety of immume checkpoint inhibitor PD-1 SHR1210 combined with Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of locally advanced resectable gastric and gastroesophageal junction adenocarcinoma.
Gastric Cancer
DRUG: SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine
pathological complete response (pCR) rate, the rate of no residual tumor cells in both the excised gastric cancer and lymph node (ypT0N0), up to 2 year
Objective Response Rate (ORR), Defined as the proportion of patients with a documented complete response, and partial response (CR

+ PR ), up to 2 year|Overall survival(OS), From date of randomization until the date of death from any cause, up to 2 year|safety, adverse events in patients during the neoadjuvant treatment phase, up to 2 year|Disease Free Survival（DFS）, The time from the start of randomization to the first tumor recurrence/metastasis or the death of the subject for any reason, up to 2 year
This study is a prospective, one-arm, phase II clinical study to evaluate the safety and efficacy of SHR-1210 in combination with trastuzumab plus oxaliplatin and capecitabine for HER2-positive locally advanced resectable gastric adenocarcinoma and gastroesophageal junction adenocarcinoma during the perioperative treatment.